Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.49 USD
Change Today -2.10 / -3.15%
Volume 510.3K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Anacor Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $9,642,000 compared to $8,485,000 a year ago. Loss from operations was $16,991,000 compared to income from operations of $134,150,000 a year ago. Loss before benefit from income taxes of $20,382,000 compared to income before provision for income taxes of $132,454,000 a year ago. Net loss was $10,124,000 or $0.24 per diluted share compared to net income of $130,748,000 or $3.01 per diluted share a year ago. For the year, the company reported total revenues of $20,686,000 compared to $17,228,000 a year ago. Loss from operations was $90,796,000 compared to income from operations of $92,517,000 a year ago. Loss before benefit from income taxes of $97,404,000 compared to income before provision for income taxes of $86,471,000 a year ago. Net loss was $87,146,000 or $2.06 per diluted share compared to net income of $84,765,000 or $2.10 per diluted share a year ago.

Anacor Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 12, 2015

Anacor Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 12, 2015

Anacor Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Anacor Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 12, 2015

Anacor Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM

Anacor Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Paul L. Berns, Chairman, Chief Executive Officer, President, Chairman of Compensation Committee, Chairman of Transaction Committee and Member of Audit Committee.

Anacor Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Anacor Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. Revenues for the quarter ended September 30, 2014 were $4.0 million, compared to $3.6 million for the comparable period in 2013. Revenue for the three months ended September 30, 2014 was comprised of $1.1 million of revenue related to the distribution and commercialization agreement with Sandoz (the Sandoz Agreement) and $2.9 million of research contract revenue. Loss from operations was $30.275 million against $15.658 million a year ago. Net loss was $31.342 million or $0.74 per basic and diluted share against net loss of $16.809 million or $0.41 per basic and diluted share a year ago. For the nine months, the company reported total revenue of $11.044 million against $8.743 million a year ago. Loss from operations was $73.805 million against $41.633 million a year ago. Net loss was $77.022 million or $1.83 per basic and diluted share against net loss of $45.983 million or $1.19 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $64.49 USD -2.10

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 134.0x
Price/Book 35.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 125.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.